71 lines
4.6 KiB
Markdown
71 lines
4.6 KiB
Markdown
---
|
||
type: source
|
||
title: "Noom GLP-1 Engagement Report: 2.2x Longer Persistence for High-Engagement Users (January 2026 Analysis)"
|
||
author: "Noom (internal engagement report, published February 4, 2026)"
|
||
url: https://www.noom.com
|
||
date: 2026-02-04
|
||
domain: health
|
||
secondary_domains: []
|
||
format: report
|
||
status: null-result
|
||
priority: medium
|
||
tags: [glp1, adherence, behavioral-wraparound, digital-health, noom, engagement, persistence]
|
||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||
---
|
||
|
||
## Content
|
||
|
||
Noom Engagement Report (January 2026 analysis, published February 4, 2026):
|
||
|
||
**Sample:** 30,239 members for persistence analysis; 14,203 for weight loss metrics. Cohort: started GLP-1 programs December 2024–February 2025.
|
||
|
||
**Methodology:** Members stratified into engagement quartiles by app opens (capped at 20/day).
|
||
- Bottom quartile (Q1): 244.7 app opens
|
||
- Top quartile (Q4): 2,162.2 app opens
|
||
- Statistical significance confirmed (p < 0.001)
|
||
|
||
**Persistence outcomes:**
|
||
- Top engagement quartile persisted on GLP-1 medication 2.2x longer than bottom quartile within first 12 months
|
||
- Q1 (lowest engagement): 2.8 months median persistence
|
||
- Q4 (highest engagement): 6.2 months median persistence
|
||
|
||
**Weight loss outcomes:**
|
||
- Top quartile lost 25.2% more weight at week 40 vs. bottom quartile
|
||
- Absolute difference: approximately 8.3 additional pounds
|
||
|
||
**Retention signal:**
|
||
- Day-30 engagement: 40% of December cohort returned on day 30 (claimed 10x higher than digital health app average)
|
||
|
||
**Noom GLP-1 product suite:**
|
||
1. GLP-1 Companion: behavioral support layer for people already prescribed GLP-1s elsewhere
|
||
2. GLP-1Rx (Microdose program): Noom prescribes medication + behavioral program, starting at $119/month
|
||
3. Components: AI food logging, medication tracking, side effect support, body composition scanning, glucose forecasting, muscle preservation ("Muscle Defense"), gamification
|
||
|
||
**PDURS positioning:** Noom updated GLP-1 Companion to prepare for FDA's expected Prescription Drug Use-Related Software (PDURS) framework — attempting to position as regulated software companion to GLP-1 prescriptions.
|
||
|
||
**Explicit limitation noted by Noom itself:**
|
||
"These findings reflect observational analyses and report associations/correlations, not proof that engagement causes improved outcomes." Reverse causality acknowledged: people doing well on medication may engage more with app.
|
||
|
||
## Agent Notes
|
||
**Why this matters:** The 2.2x persistence improvement for high-engagement vs. low-engagement users is the clearest engagement dose-response signal in the behavioral wraparound literature. Noom is unusual in explicitly noting the reverse causality caveat in their own report.
|
||
|
||
**What surprised me:** That Noom acknowledged reverse causality in their own internal analysis. Most company reports present favorable data without explicitly flagging the confound. This is either genuine methodological integrity or savvy pre-emption of criticism.
|
||
|
||
**What I expected but didn't find:** Any randomized comparison of high vs. low engagement (randomizing app access to test causal effect). This doesn't exist from Noom. Also no post-discontinuation data — Noom only reports persistence ON medication, not maintenance after stopping.
|
||
|
||
**KB connections:**
|
||
- Behavioral adherence thread (this session)
|
||
- GLP-1 persistence data (14.3% two-year adherence baseline from Sessions 20-22)
|
||
- Digital health intervention effectiveness claims
|
||
|
||
**Extraction hints:**
|
||
- The 2.2x persistence finding is extractable as an observational signal, but confidence should explicitly acknowledge the reverse causality problem
|
||
- More useful as a data point in a broader behavioral wraparound claim than as a standalone
|
||
- The PDURS positioning is separately interesting for the regulatory/atoms-to-bits boundary claims — Noom is explicitly trying to convert a behavioral app into regulated prescription software
|
||
|
||
**Context:** Noom is a commercial digital health company with significant GLP-1 market aspirations. The $119/month price for their microdose program is substantially cheaper than branded GLP-1s alone. They have financial incentives to show engagement drives outcomes.
|
||
|
||
## Curator Notes (structured handoff for extractor)
|
||
PRIMARY CONNECTION: Behavioral wraparound for GLP-1 adherence; digital health intervention effectiveness
|
||
WHY ARCHIVED: Provides engagement dose-response data for the behavioral wraparound claim; the reverse causality acknowledgment is noteworthy as methodological transparency
|
||
EXTRACTION HINT: Use as one of 4-5 behavioral wraparound data points, noting the reverse causality caveat. The PDURS positioning detail is separately interesting for regulatory/digital health extractor.
|